The Gambia Liver Cancer Study: Infection with Hepatitis B and C and the Risk of Hepatocellular Carcinoma in West Africa

Hepatology

Volumn 39, Issue 1, 2004, Pages 211-219

  Kirk, Gregory D ^a,b   Lesi, Olufunmilayo A ^b,g   Mendy, Maimuna ^d   Akano, Aliu O ^e,h   Sam, Omar ^e   Goedert, James J ^a   Hainaut, Pierre ^c   Hall, Andrew J ^f   Whittle, Hilton ^d   Montesano, Ruggero ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Intl Agency for Research on Cancer   (Gambia)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e Royal Victoria Teaching Hospital Gambia   (Gambia)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^h NATIONAL HOSPITAL   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; DISEASE TRANSMISSION; ENDEMIC DISEASE; EXPOSURE; FEMALE; GAMBIA; GENDER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; AGE DISTRIBUTION; LIVER TUMOR; MIDDLE AGED; RISK FACTOR; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; ENDEMIC DISEASES; FEMALE; GAMBIA; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION;

EID: 1442306660     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20027     Document Type: Article

References (50)

1. IARC. Hepatitis viruses. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 59. Lyon, France: International Agency for Research on Cancer, 1994.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-S66.
3. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17:71-91.
4. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
5. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. HEPATOLOGY 2002;36(5 Suppl):S74-S83.
6. Deuffic S, Poynard T, Valleron AJ. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 1999;6:411-413.
7. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci 1993;253:197-201.
8. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
9. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001;358: 1989-1992.
10. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
11. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002;2:293-302.
12. WHO Viral Hepatitis Prevention Board. Global surveillance and control of hepatitis C. J Viral Hepat 1999;6:35-47.
13. Hadziyannis S, Tabor E, Kaklamani E, Tzonou A, Stuver S, Tassopoulos N, Mueller N, et al. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 1995;60: 627-631.
14. Kaczynski J, Hansson G, Hermodsson S, Olsson R, Wallerstedt S. Minor role of hepatitis B and C virus infection in the etiology of hepatocellular carcinoma in a low-endemic area. Scand J Gastroenterol 1996;31:809-813.
15. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996;73:1498-1502.
16. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997;112:184-187.
17. Yu SZ, Zi XL, Chen G. [The relationship between viral hepatitis and primary liver cancer in four areas of China]. Zhonghua Liu Xing Bing Xue Za Zhi 1997;18:214-216.
18. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. Br J Cancer 2001;84:1207-1214.
19. Whittle H, Inskip H, Bradley AK, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990;161: 1112-1115.
20. Vall Mayans M, Hall AJ, Inskip HM, et al. Risk factors for transmission of hepatitis B virus to Gambian children. Lancet 1990;336:1107-1109.
21. Whittle HC, Bradley AK, McLauchlan K, et al. Hepatitis B virus infection in two Gambian villages. Lancet 1983;1:1203-1206.
22. Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, Hall A, Whittle H, et al. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J Hepatol 2001;35:99-104.
23. Mendy, ME, Whittle HC, O'Donovan D, Kekule AS. Prevalence of hepatitis C and GB virus infection in The Gambia. Br J Biomed Sci 1998;55: 92-93.
24. The Gambia Hepatitis Study Group. The Gambia Hepatitis Intervention Study. Cancer Res 1987;47:5782-5787.
25. Evans AA, O'Connell AP, Pugh JC, Mason WS, Shen FM, Chen GC, Lin WY, et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-565.
26. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996;117:313-325.
27. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15(Suppl):E25-E30.
28. Payne RJ, Nowak MA, Blumberg BS. The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:6542-6546.
29. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-5S.
30. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999;31(Suppl 1):25-30.
31. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355: 887-891.
32. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
33. Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, Asakura H. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001;16: 1274-1281.
34. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. HEPATOLOGY 2002;35:1274-1276.
35. Dumpis U, Mendy M, Hill A, Thursz M, Hall A, Whittle H, Karayiannis P. Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. J Med Virol 2001;65:664-670.
36. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. HEPATOLOGY 1998;27:383-391.
37. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-1150.
38. Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of heparocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996;20(1 Suppl):91A-94A.
39. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, Tamai S, et al. The male preponderance in incidence of hepatocellular carcinoma in cirrhotic patients may depend on the higher DNA synthetic activity of cirrhotic tissue in men. Cancer 1993;72:369-374.
40. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. HEPATOLOGY 2001;34: 523-528.
41. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
42. Shiratori Y, Shiina S, Zhang PY, Ohno E, Okudaira T, Payawal DA, Ono-Nita SK, et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997;80:2060-2067.
43. Pontisso P, Gerotto M, Benvegnu L, Chemello L, Alberti A. Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther 1998;3(Suppl): 137-142.
44. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
45. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000;10:211-231.
46. Ryder RW, Whittle HC, Sanneh AB, Ajdukiewicz AB, Tulloch S, Yvonnet B. Persistent hepatitis B virus infection and hepatoma in The Gambia, West Africa. A case-control study of 140 adults and their 603 family contacts. Am J Epidemiol 1992;136:1122-1231.
47. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, Whittle HC. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999;17:2946-2950.
48. Kirk GD. Hepatitis B vaccination and liver cancer. In: Stewart BW, Kleihues P, eds. World Cancer Report. Lyon, France: IARC Press, 2003;144-147.
49. Hall AJ. Vaccination politics. Trop Med Int Health 2003;8:1-2.
50. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47-S49.